📰 Immunic News
Page 8 - Immunic News Today
Fast, Ad-Free News Updates
Stay updated with breaking news from Immunic. Real-time updates on events, politics, business and more.
November 10, 2022
Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Investor and Scientific Conferences in November and December 10.11.2022 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate in Investor and Scientific Conferences ...
November 10, 2022
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...
November 10, 2022
Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Investor and Scientific Conferences in November and December 10.11.2022 / 12:30 CET/CEST The issuer is solely
November 3, 2022
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...
October 20, 2022
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...
October 4, 2022
Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Scientific and Industry Conferences in October 04.10.2022 / 12:30 CET/CEST The issuer is solely responsible
October 4, 2022
/PRNewswire/ -- Immunic, Inc. (Nasdaq: IMUX), a clinical-stage biopharmaceutical company developing a pipeline of selective oral immunology therapies focused...
October 4, 2022
Issuer: Immunic, Inc. / Key word(s): Conference Immunic to Participate in Scientific and Industry Conferences in October 04.10.2022 / 12:30 CET/CEST The issuer is solely responsible for the content of this announcement. Immunic to Participate in Scientific and Industry Conferences in October NEW...
September 20, 2022
Issuer: Immunic, Inc. / Key word(s): Study results Immunic Announces Positive Results from Single and Multiple Ascending Dose Parts of Its Phase 1 Clinical Trial of IMU-856 in Healthy Human
September 1, 2022
Issuer: Immunic, Inc. / Key word(s): Conference Immunic, Inc. to Participate in Investor Conferences in September 01.09.2022 / 12:30 CET/CEST The issuer is solely responsible for